Ophthalmology Therapeutic Roundup — September 29, 2016

Here's a look at some of the latest news regarding ophthalmic drugs and therapies from the past week. 

• Ophthalmic pharmaceutical and medical device company Avedro, Inc. is reportedly now shipping Photrexa Viscous and Photrexa, the drugs used in corneal cross-linking procedures with the KXL System. According to Avedro, clinicians in the U.S. have already started to treat their patients who are suffering from progressive keratoconus or corneal ectasia.
• Specialty pharmaceutical company EyeGate Pharmaceuticals, Inc. recently announced that its wholly-owned subsidiary Jade Therapeutics, Inc. has eceived the second year of funding of $448,185 from the U.S. Army Medical Research and Materiel Command (USAMRMC) to continue the development of its proprietary thiolated hyaluronic acid (CMHA-S) for use as an ocular bandage film. EyeGate reportedly uses a biocompatible hydrogel material for repairing the ocular surface and for sustained drug delivery to enhance the treatment of ophthalmic disorders and improve visual outcomes for both the military and civilian populations.
• And MD Stem Cells has been named a collaborator for the new Stem Cell Ophthalmology Treatment Study (SCOTS), which will be conducted in Florida. The study will reportedly examine using bone marrow-derived stem cells as a treatment option for retinal and optic nerve diseases.